Effectiveness, safety and predictors of response to vedolizumab as first- or second-line biological therapy in patients with ulcerative colitis: A real-world observational multicenter study. - Ferreira, S.; Parra, R. Serafim; Sassaki, L. Yukie [UNESP]; Parente, J. M. Luz; Mello, M. Kurtz de; Chebli, L. Andrade; Luporini, R. L.; Alves Junior, A. J. Tiburcio; Nobrega, F. J. Firmino; Silva, B. C. da; Miranda, E. F.; Quaresma, A. Botelho; et al. (Oxford Univ Press, 2025)